Heartflow earnings release, August 13, 2026

Heartflow, Inc. (HTFL) · Form 8-K, Item 2.02 · Filed · SEC filing

Heartflow Reports

Second

Quarter 202⁶

Financial Results and Raises Full Year 2026 Guidance

SAN FRANCISCO — August¹³, 202⁶ – Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for diagnosing coronary artery disease (CAD), today reported financial results for the second quarter ended

June³⁰, 202⁶.

Second

Quarter 202⁶

Highlights

2026 Annual Guidance

"The second quarter reflects the growing strength of Heartflow's category leadership and unique

AI technology platform for identifying, diagnosing, managing and treating coronary artery disease," said John Farquhar, President and CEO of Heartflow. "The CCTA market for detecting CAD continues to grow rapidly and remains significantly under-penetrated, providing a strong backdrop for continued growth. Our FFR

CT business remains strong and durable, while Plaque is rapidly emerging as a meaningful second growth engine — helping us win new accounts, deepen physician utilization and expand the value of the Heartflow platform for our customers. At the same time, record gross margin and improving operating leverage demonstrate the increasing scalability of our model, giving us greater confidence in long-term, profitable growth."

Second

Quarter 202⁶

Financial Results

Total revenue was $64.1 million, a 48% increase year-over-year. U.S. revenue was $59.6 million, a 51% increase year-over-year. International and other revenue was $4.5 million, a 12% increase year-over-year. The year-over-year increase in total global revenue was primarily attributable to an increase in total U.S. FFR

CT revenue case volume and an increase in total U.S. Plaque revenue case volume.

Gross profit was $53.2 million, compared to $32.8 million in the prior year period. Non-GAAP gross profit was $53.4 million, compared to $32.8 million in the prior year period.

Gross margin was 83.0%, compared to 75.5% in the prior year period. Non-GAAP gross margin was 83.3%, compared to 75.6% in the prior year period. The year-over-year gross margin expansion was primarily attributable to an increase in total revenue case volume, an increase in total U.S. Plaque revenue case volume, and improved production team productivity driven by AI efficiency initiatives, partially offset by the hiring and training of production team personnel.

Total operating expenses were $71.1 million, or 111% of total revenue, compared to $46.5 million, or 107% of total revenue, in the prior year period. Non-GAAP total operating expenses were $61.3 million, or 96% of total revenue, compared to $44.3 million, or 102% of total revenue, in the prior year period. The year-over-year operating expense increase was primarily attributable to increased investment in sales personnel and related expenses, as well as increased investments in technology and clinical research.

Net operating loss was $17.9 million, compared to $13.7 million in the prior year period. Non-GAAP net operating loss was $7.9 million, compared to $11.5 million in the prior year period.

Net loss was $15.7 million, or ($0.18) net loss per share, compared to $9.2 million, or ($1.46) net loss per share, in the prior year period. Non-GAAP net loss was $5.8 million, or ($0.07) non-GAAP net loss per share, compared to $17.6 million, or ($2.79) non-GAAP net loss per share, in the prior year period.

Adjusted EBITDA was ($6.7) million, compared to ($10.1) million in the prior year period.

Cash, cash equivalents and investments totaled $246.8 million as of June 30, 2026.

For additional information regarding non-GAAP financial measures, see “Use of Non-GAAP Measures,” “Heartflow GAAP to Non-GAAP Reconciliations” and “Reconciliation of GAAP Net Loss to Adjusted EBITDA” below.

Webcast and Conference Call Details

Heartflow will host a conference call today,

August¹³, 2026, at 1:30 p.m. PT / 4:30 p.m. ET to discuss its second quarter 202⁶ financial results. Those interested in listening to the conference call should register online using this link. Once registered, participants will receive dial-in numbers and a unique

PIN to join the call. Participants are encouraged to register more than 15 minutes prior to the start of the call. A live and archived webcast of the event will also be available on the “Investor Relations” section of the Heartflow website at https://ir.heartflow.com/. The archived version will be available for 12 months following completion of the live call.

About Heartflow’s Technology and Research

Heartflow’s technology is redefining precision cardiovascular care through clinically-proven AI and the world’s largest coronary imaging dataset. Heartflow has been adopted by more than 1,⁸

00 institutions globally and continues to strengthen its commercial presence to make this cutting-edge solution more widely available to an increasingly diverse patient population. Backed by American College of Cardiology and American Heart Association (ACC/AHA) guidelines and supported by more than 6²⁵ peer-reviewed publications, Heartflow has redefined how clinicians manage care for more than⁷⁵

0,000 patients worldwide.¹

Key benefits include: evidence to improve patient outcomes.

2,3,4,5

Proven in real-world practice with reproducibility and accuracy, Heartflow’s coronary CTA image acceptance rates exceed 9⁷

%.

About Heartflow, Inc.

Heartflow is transforming coronary artery disease from the world’s leading cause of death into a condition that can be detected early, diagnosed accurately, and managed for life. The

Heartflow One... (truncated)providing clinically meaningful, actionable insights into plaque location, volume, and composition and its effect on blood flow — all without invasive procedures. Discover how we’re shaping the future of cardiovascular care at heartflow.com.

Use of Non-GAAP Measures

To supplement its consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company discloses non-GAAP gross profit and non-GAAP gross margin, non-GAAP total operating expenses, non-GAAP research and development expense, non-GAAP selling, general and administrative expense, non-GAAP net operating loss, non-GAAP net loss, non-GAAP net loss per share, basic and diluted, and Adjusted EBITDA (collectively, the “Non-GAAP Measures”) in this press release. As used by the Company, these measures are adju s ted to exclude stock-based compensation expense from the comparable GAAP financial measure. Non-GAAP net loss and non-GAAP net loss per share, basic and diluted, are also adjusted for change in fair value of common stock warrant liability, change in fair value of derivative liability, certain litigation expenses and asset impairment charge. In addition, Adjusted EBITDA is calculated by adding back to net loss or excluding, as appropriate, interest income and expense, provision for income taxes, certain litigation expenses, and charges for depreciation and amortization and is further adjusted by adding back in or excluding, stock-based compensation and, as appropriate, other income and expense items that are not reflective of the Company’s underlying continuing operating performance. Reconciliations of the Non-GAAP Measures to their most directly comparable GAAP financial measures are provided in the financial statement tables included at the end of this press release, and investors are encouraged to review the reconciliations. The Company believes the presentation of the Non-GAAP Measures, when shown in conjunction with the corresponding GAAP measures, provides useful information to investors as it provides visibility to the Company’s underlying continuing operating performance from period to period by excluding the impact of stock-based compensation and certain other items that are not reflective of the Company’s ongoing operations. Because of the variety of equity awards used by companies, the varying methodologies for determining stock-based compensation expense, the subjective assumptions used in those determinations, and the volatility in valuations that can be driven by market conditions outside the Company’s control, we believe excluding stock-based compensation expense enhances the ability of management and investors to understand and assess the underlying performance of our business over time and compare it against our peers, a majority of whom also exclude stock-based compensation expense from their non-GAAP results. With respect to the presentation of Adjusted EBITDA, the Company believes it is a useful measure to evaluate the Company’s operating performance and it is used by the Company to evaluate ongoing operations and for planning and forecasting purposes. Adjusted EBITDA is also a measure frequently used by analysts, investors and other interested parties to evaluate companies in our same industry.

The Company’s definition of the Non-GAAP Measures may differ from similarly titled measures used by others. The Non-GAAP Measures should be considered only as a supplement to, and not as a substitute for, or superior to, their most directly comparable GAAP financial measures. Because the Non-GAAP Measures exclude the effect of items that increase or decrease the Company’s reported results of operations, management strongly encourages investors to review the reconciliations to the most comparable GAAP financial measures at the end of this press release and, when they become available, the Company’s consolidated financial statements and publicly filed Securities and Exchange Commission (“SEC”) reports in their entirety.

The Company is not able to provide a reconciliation without unreasonable efforts of its forward-looking guidance related to non-GAAP gross margin to the most directly comparable GAAP financial measure due to the unknown effect of stock-based compensation that is material to the comparable GAAP financial measure.

Financial statements

Income Statement

Three Months Ended — 

Three Months Ended – June 30, – 2026Three Months Ended – June 30, – 2025Six Months Ended – June 30, – 2026Six Months Ended – June 30, – 2025
Revenue64,08243,424116,66980,629
Cost of revenue10,89210,64621,31519,910
Gross profit53,19032,77895,35460,719
Operating Expenses:Research and development26,26115,03247,88128,956
Operating Expenses:Selling, general and administrative44,82931,46187,39562,980
Operating Expenses:Asset impairment charge7,482
Operating Expenses:Total operating expenses71,09046,493142,75891,936
Operating Expenses:Loss from operations-17,900-13,715-47,404-31,217
Operating Expenses:Interest income2,3056354,7691,178
Operating Expenses:Interest expense-6,621-3-11,714
Operating Expenses:Change in fair value of common stock warrant liability-863-2,469
Operating Expenses:Change in fair value of derivative liability11,5382,493
Operating Expenses:Other income (expense), net-126-111-440247
Operating Expenses:Loss before provision for income taxes-15,721-9,137-43,078-41,482
Operating Expenses:Provision for income taxes-22-59-45-59
Operating Expenses:Net loss-15,743-9,196-43,123-41,541
Comprehensive loss:Net loss-15,743-9,196-43,123-41,541
Other comprehensive loss:Foreign currency translation gain (loss)-929125355
Other comprehensive loss:Unrealized loss on investments, net-204-726
Other comprehensive loss:Total other comprehensive loss-213291-47355
Other comprehensive loss:Total comprehensive loss-15,956-8,905-43,596-41,486
Net loss per share, basic and diluted-0.18-1.46-0.5-6.66
Weighted-average shares used to compute net loss per share, basic and diluted86,398,7786,316,31586,021,3236,240,885

Income Statement

Three Months Ended June 30, 2026 — 

Three Months Ended June 30, 2026 – GAAPThree Months Ended June 30, 2026 – AdjustmentsThree Months Ended June 30, 2026 – Non-GAAPThree Months Ended June 30, 2025 – GAAPThree Months Ended June 30, 2025 – AdjustmentsThree Months Ended June 30, 2025 – Non-GAAP
Gross profit53,19017353,36332,7784532,823
Gross margin83.0%0.3%83.3%75.5%0.1%75.6%
Operating Expenses:Research and development26,261-2,73223,52915,032-38114,651
Operating Expenses:Selling, general and administrative44,829-7,07137,75831,461-1,82729,634
Operating Expenses:Total operating expenses71,090-9,80361,28746,493-2,20844,285
Loss from operations-17,9009,976-7,924-13,7152,253-11,462
Net loss-15,7439,976-5,767-9,196-8,422-17,618
Net loss per share, basic and diluted-0.180.11-0.07-1.46-1.33-2.79

Income Statement

Six Months Ended June 30, 2026 — 

Six Months Ended June 30, 2026 – GAAPSix Months Ended June 30, 2026 – AdjustmentsSix Months Ended June 30, 2026 – Non-GAAPSix Months Ended June 30, 2025 – GAAPSix Months Ended June 30, 2025 – AdjustmentsSix Months Ended June 30, 2025 – Non-GAAP
Gross profit95,35434095,69460,71910260,821
Gross margin81.7%0.3%82.0%75.3%0.1%75.4%
Operating Expenses:Research and development47,881-4,87143,01028,956-92828,028
Operating Expenses:Selling, general and administrative87,395-11,73675,65962,980-3,71559,265
Operating Expenses:Asset impairment charge7,482-7,482$-$-$-$-
Operating Expenses:Total operating expenses142,758-24,089118,66991,936-4,64387,293
Loss from operations-47,40424,429-22,975-31,2174,745-26,472
Net loss-43,12324,429-18,694-41,5414,721-36,820
Net loss per share, basic and diluted-0.50.28-0.22-6.660.76-5.9

Income Statement

Three Months Ended — 

Three Months Ended – June 30, – 2026Three Months Ended – June 30, – 2025Six Months Ended – June 30, – 2026Six Months Ended – June 30, – 2025
GAAP net loss-15,743-9,196-43,123-41,541
Non-GAAP adjustments:Interest (income) expense, net-2,3055,986-4,76610,536
Non-GAAP adjustments:Asset impairment charge7,482
Non-GAAP adjustments:Change in fair value of common stock warrant liability8632,469
Non-GAAP adjustments:Change in fair value of derivative liability-11,538-2,493
Non-GAAP adjustments:Other (income) expense, net126111440-247
Non-GAAP adjustments:Provision for income taxes22594559
Non-GAAP adjustments:Certain litigation expenses2,0642,481
Non-GAAP adjustments:Depreciation and amortization1,2201,3952,6432,767
Non-GAAP adjustments:Stock-based compensation expense7,9122,25314,4664,745
Non-GAAP adjustments:Adjusted EBITDA-6,704-10,067-20,332-23,705

Balance Sheet

December 31, — 

June 30, – 2026December 31, – 2025
Current assetsCash and cash equivalents34,36244,776
Current assetsShort-term investments128,189132,010
Current assetsAccounts receivable, net42,76129,343
Current assetsPrepaid expenses and other current assets18,65714,075
Current assetsTotal current assets223,969220,204
Current assetsLong-term investments84,289103,365
Current assetsProperty and equipment, net9,6468,587
Current assetsOperating lease right-of-use assets15,23617,488
Current assetsRestricted cash, non-current4,7024,709
Current assetsOther non-current assets6,6215,099
Current assetsTotal assets344,463359,452
Full release

Forward-Looking Statements

This press release contains express or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release, including statements regarding our strategy, market conditions, expected market growth and financial guidance, are forward-looking statements. These forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements, including, but not limited to: we may not be able to achieve or sustain profitability; our dependence on the success of our two products, Heartflow FFR

CT... (truncated) with our dependence on our information technology systems; security breaches that we cannot anticipate or successfully defend; extensive regulatory requirements we face to bring our products to market; and third parties could develop and commercialize technology and products similar or identical to ours. For a more extensive description of these and other risks and uncertainties that could materially affect our results, you should read our filings with the SEC, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as such filings may be amended, supplemented or superseded from time to time by other reports Heartflow files with the SEC. You should not place undue reliance on the forward-looking statements in this press release, which speak only as of the date hereof, and we undertake no obligation to update the forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

Investor Contact

Nick Laudico nlaudico@heartflow.com

Media Contact

Elliot Levy elevy@heartflow.com

_________________________¹

Gulati, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation & Diagnosis of Chest Pain. J Am Coll Cardiol²

Narula, et al. EHJ CVI 2024³

Danad, et al. JAMA Cardiol 2017⁴

Fairbairn et al. Coronary CT Angiography Plaque as a Predictor of Death, Cardiovascular Death and Myocardial Infarction. Presented at AHA 2025. (Real-world study with n=7,899 patients, higher TPV results in increased cardiovascular death and MI)⁵

Madsen KT, et al. ADVANCE-DK 7-year. Presented at TCT Scientific Sessions 2024 (n=900 patients determined a 2.5x increase in cardiovascular events or deaths at 7 years)

Heartflow, Inc.

Consolidated Statements of Operations

Data

(unaudited, in thousands, except share and per share data)

Heartflow, Inc.

Consolidated Balance Sheets

Data

(unaudited, in thousands)

Heartflow, Inc.

GAAP to Non-GAAP Reconciliations

(unaudited, in thousands except for per share amounts and percentage data)

(a)

Represents adjustments related to stock-based compensation expense

(b)

Represents adjustments for: (i) stock-based compensation expense of $5.0 million; and (ii) certain litigation expenses of $2.1 million

(c)

Represents adjustments for: (i) stock-based compensation expense of $7.9 million; and (ii) certain litigation expenses of $2.1 million

(d) Represents adjustments for: (i) stock-based compensation expense of $2.3 million; (ii) change in fair value of common stock warrant liability of $0.9 million; and (iii) change in fair value of derivative liability of $11.5 million

( a)

Represents adjustments related to stock-based compensation expense

(b)

Represents adjustments for: (i) stock-based compensation expense of $9.3 million; (ii) certain litigation expenses of $2.5 million; and (iii) asset impairment charge of $7.5 million

(c)

Represents adjustments for: (i) stock-based compensation expense of $14.5 million; (ii) certain litigation expenses of $2.5 million; and (iii) asset impairment charge of $7.5 million

(d)

Represents adjustments for: (i) stock-based compensation expense of $4.7 million; (ii) change in fair value of common stock warrant liability of $2.5 million; and (iii) change in fair value of derivative liability of $2.5 million

Heartflow, Inc.

Reconciliation of GAAP Net Loss to Adjusted EBITDA

(unaudited, in thousands)

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Heartflow earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.